lifestyle.marketresearchjournals.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting
April 22, 2026
Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
April 21, 2026
Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences
April 13, 2026
Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
March 17, 2026
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
March 12, 2026
Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
February 20, 2026
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants
February 19, 2026
Eupraxia Pharmaceuticals Announces Proposed Public Offering
February 18, 2026